Lexicon Genetics - Eine Chance ? - 500 Beiträge pro Seite

[Tanzbaerli]

25.11.2003
Lexicon Genetics Kaufempfehlung
Global Biotech Investing

Die Experten des Börsenbriefes "Global Biotech Investing" empfehlen den Titel von Lexicon Genetics (ISIN US5288721047/ WKN 936717) zum Kauf.

Das Unternehmen forsche intensiv im Genomics-Sektor und damit in einem Bereich, der in den letzten Jahren nicht gerade zu den Lieblingsbereich der Investoren gezählt habe. Lexicon habe eine einzigartige Gensequenzierung entwickelt, die es erlaube, etwa 750 Gene pro Jahr zu analysieren und daraus 2% bis 3% als potenzielle Target-Kandidaten für eine Wirkstoffbehandlung zu identifizieren. Seit dem Jahr 2000 habe das Unternehmen seine Umsätze von 14,6 Mio. auf 41,5 Mio. erhöhen können. Der Kurs des Titels sei in diesem Zeitraum allerdings von 40 auf 5 USD gefallen.

Die ersten Forschungsreihen würden dabei durchaus Erfolge zeigen. Schon vor wenigen Monaten habe das Unternehmen Details zu LG 617 verkündet, einem Gen, das möglicherweise Ansatzpunkte zur Alzheimer-Behandlung biete. Zudem habe man ein Gen identifizieren können, welches einen völlig neuen Ansatz für die Behandlung von Bluthochdruck ergeben könnte.

Der Titel sei daraufhin gleich nach oben gegangen. Für einen Ausbruch aus der seit Monaten bestehenden Range zwischen 5 und 6 USD habe es allerdings noch nicht gereicht. Internationale Investmenthäuser seien sich aber sicher, dass eine Anlage mittelfristig mit satten Gewinnen belohnt werde. Zudem würden Übernahmegerüchte die Runde machen. Sollte das Unternehmen in Zukunft eine Kooperation mit einem Big Player bekannt geben, würden die Analysten von Punk, Ziegel & Co. eine schnelle Kursrallye in den Bereich von 12 USD erwarten.

Die Experten vom "Global Biotech Investing" raten den Anlegern rechtzeitig mit einer kleinen Position bei Lexicon Genetics einzusteigen. Des weiteren empfehle man einen Stop-loss bei 3,90 EUR zu setzen.

-------------------------------------------------------

19.12.2003
Lexicon Genetics "buy"
Punk Ziegel & Co.

Rating-Update:

Die Analysten vom Investmenthaus Punk Ziegel & Co stufen die Aktie von Lexicon Genetics (ISIN US5288721047/ WKN 936717) unverändert mit "buy" ein. Das Kursziel werde bei 24 USD gesehen.

[pechel]

Hallo
Habe heute bei 5.-Euro nachgekauft,habe von einem guten Bekannten aus den USA der in dem Sektor arbeitet erfahren es kommt demnächst zu einer super Neuigkeit!!!
Auf steigende Kurse
Gruß
Pechel

[meislo]

Hallo pechel

Über den Inhalt der news hat er sich ausgeschwiegen???

gruss meislo

[pechel]

Hallo Meislo!

Es betrifft die Forschungsreihen mit einem Gen, das möglicherweise Ansatzpunkte zur Alzheimer-Behandlung biete.Mehr kann ich auch nicht dazu sagen und alles natürlich nur unter Vorbehalt.Jeder muss selbst Entscheiden was er davon hält.
Gruss
Axel

[meislo]

Danke Axel

Alzheimer ist eine alterskrankheit und wir werden immer älter also bietet ein behandlungsansatz in diesem bereich enorme chancen. auf diesem gebiet sind auch die stammzellenfirmen aktiv.



Für alle lexg-investierten ein muss

Lexicon Genetics to Present at the 22nd Annual JPMorgan Healthcare Conference
Tuesday January 6, 4:30 pm ET


THE WOODLANDS, Texas, Jan. 6 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - News) announced today that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Lexicon, will speak at the 22nd Annual JPMorgan Healthcare Conference in San Francisco at 8:30 a.m. PST on Thursday, January 15, 2004. Dr. Sands will provide an overview of Lexicon, discuss its recently announced drug development collaboration with Bristol- Myers Squibb Company and review corporate objectives for 2004.
ADVERTISEMENT


A live webcast of Dr. Sands` presentation may be accessed on Lexicon`s corporate website at www.lexicon-genetics.com . An archived version of the webcast will be available on the website through January 23, 2004.

About Lexicon Genetics

Lexicon Genetics is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. Lexicon is using gene knockout technology to systematically discover in living mammals, or in vivo, the physiological functions and pharmaceutical utility of genes. The Company`s gene function discoveries fuel therapeutic discovery programs in diabetes, obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. Lexicon has established drug discovery alliances and functional genomics collaborations with leading pharmaceutical and biotechnology companies, research institutes and academic institutions throughout the world to commercialize its technology and turn its discoveries into drugs. Additional information about Lexicon is available through its corporate website, www.lexicon-genetics.com .


Also der 15 Januar könnte spannend werden


gruss meislo

[Tanzbaerli]

Hallo Meislo!!

Freut mich daß mal jemand außer mir Lexicon entdeckt hat bzw. was dazu schreibt.

Mich verblüfft das hohe Kursziel von 24$ (siehe obiges Posting). Bin vor Weihnachten in den Wert rein und bisher läuft es ja blendend!

Ich schätze das Risoko bei dem Wert nicht so hoch ein wie bei anderen Werten dieser Sparte und Chancen sollten genug vorhanden sein!

... Bärli

[meislo]

Press Release Source: Lexicon Genetics Incorporated


Lexicon Genetics Has Initiated More Than 40 Drug Discovery Programs From Its Genome5000(TM) Program
Tuesday January 13, 7:30 am ET


THE WOODLANDS, Texas, Jan. 13 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - News) announced today that its Genome5000 program for drug development has yielded more than 40 drug discovery programs. These drug discovery programs are in the fields of diabetes, obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. Thirteen of the programs have been contributed to Lexicon`s recently announced neuroscience drug development alliance with Bristol-Myers Squibb Company. Lexicon expects to establish additional collaborations for some of its other programs as a complement to its internal drug discovery efforts in 2004.
ADVERTISEMENT


In its Genome5000 program, Lexicon is analyzing 5,000 genes using its proprietary gene knockout technologies and its extensive physiological and behavioral analyses to discover novel drug targets from the human genome. Based on this physiological and behavioral information, Lexicon selects targets for its drug discovery programs that, when knocked out, exhibit favorable therapeutic profiles for the development of drugs. To date, Lexicon has completed the analysis of more than 1,400 genes. Lexicon expects to fully analyze an additional 900 genes in 2004.

Lexicon`s Genome5000 Program is focused on the discovery of the functions in mammalian physiology of protein families selected based on their desirable characteristics for pharmaceutical development, such as G-protein coupled receptors (GPCRs), nuclear hormone receptors, ion channels, transporters, kinases, proteases, key enzymes and secreted proteins.

"Our analysis of the in vivo function of more than 1,400 genes has given us excellent information on which human genes are the best targets for drug development," said Arthur T. Sands, M.D., Ph.D., Lexicon`s president and chief executive officer. "We believe that each of our more than 40 drug discovery programs represents an important biological finding and a compelling pharmaceutical opportunity to address a major unmet medical need."

Lexicon`s most advanced drug development programs include LG617 for Alzheimer`s disease and cognition, LG653 for obesity and diabetes, LG314 for obesity and diabetes and LG152 for solid tumors.

About Lexicon Genetics

[Tanzbaerli]

Vorab-Tipp zum neuen Depot! (15.01.2004)

Die Auflage eines neuen Depots wird von kommenden Montag an die Aufmerksamkeit Vieler auf „Global Biotech Investing“ lenken. Schon heute stellen die Experten in ihrer Daily-Ausgabe eine Aktie vor, die sicherlich Einzug ins Musterdepot halten wird. Der schnellstmögliche Einstieg wird empfohlen: Lexicon Genetics (WKN 936717) wurde von uns zuletzt am 19. Dezember besprochen, als das Unternehmen eine Forschungsallianz mit Bristol-Myers Squibb bekannt gab. Dafür fließen 30 Millionen US-Dollar an Lexicon, die in 2003 gerade einmal 40 Millionen Dollar Umsatz verbuchten. Auch technisch ist die Entwicklung beeindruckend: Der Chart ist aus der Range von 5 bis 6 US-Dollar ausgebrochen – ein Signal zum Einstieg spätestens jetzt. Den Asbruch hatten wir zum genannten Zeitpunkt gemeldet – damals stand die Aktie bei 5,63 US-Dollar. Gestern schloss sie bei 6,78 Dollar – und die Zeiten, dass sie die 10-Dollar-Marke überwindet, dürften nicht mehr fern sein. Wir empfehlen, 25 Prozent unter Einstiegskurs abzusichern und halten Sie auf dem Laufenden, was die Empfehlung seitens „Global Biotech“ betrifft.

-----------------------

Mal sehen ob sie rech haben?

Bin auf jeden Fall recht zufrieden mit diesem Wert.
22% in 1 Monat ... nur weiter so!

[Tanzbaerli]

Neuer Musterdepotwert mit Kursvervierfachung als Ziel (19.01.2004)

Als einen der „Top-Picks 2004“ stellt „Global Biotech Investing“ die Aktie dieses Genforschungsunternehmens vor. Beim Empfehlungskurs von 5,55 Euro sehen die Experten ein kurzfristiges Kursziel von 12 Euro, mittelfristig stellen sie unverändert 24 Euro Kurs in Aussicht: Lexicon Genetics (WKN 936717) hat demnach zuletzt für Aufsehen gesorgt, indem ein Gen mit Ansatzpunkten zur Alzheimerbehandlung identifiziert wurde. Ebenfalls herausgefunden wurde ein Gen, das in Tierversuchen Bluthochdruck senken konnte. Letzte Woche hatten wir vorab gemeldet, dass auch die Forschungsallianz mit Bristol-Mayers Squibb große Phantasie beinhaltet. „Global Biotech Investing“ empfiehlt Nachzüglern, schnell einzusteigen. Wir weisen neben darauf hin, dass ein Engagement neben großen Potenzial unseres Erachtens auch hohes Risiko beinhaltet. Der empfohlene Stopp-loss von 4,40 Euro sollte unbedingt beachtet werden.

---------------------------------------

Gut dass ich schon drinnen bin!

[Tanzbaerli]

20.01.2004
Lexicon Genetics Kaufempfehlung
Global Biotech Investing

Die Experten vom Börsenbrief "Global Biotech Investing" empfehlen den Titel von Lexicon Genetics (ISIN US5288721047/ WKN 936717) zum Kauf.

Laut den Wertpapierspezialisten werde das Unternehmen im laufenden Jahr mit der eigens entwickelten Gensequenzierung rund 900 Gene analysieren. Des Weiteren habe man aktuell rund 40 potenzielle Target-Kandidaten für eine Wirkstoffbehandlung in verschiedenen Testreihen. Für Aufsehen habe jüngst die Identifizierung eines Gens gesorgt, das möglicherweise Ansatzpunkte in der Alzheimerbehandlung biete.

Kurz vor Ende des Jahres habe Lexicon eine Forschungsallianz mit dem Pharma-Riesen Bristol Myers Squibb verkündet. Demnach wolle man 13 verschiedene Wirkstoffkandidaten innerhalb dieser Allianz entwickeln. Lexicon werde im Rahmen dieser Kooperation eine Vorabzahlung in Höhe von 36 Mio. USD erhalten. Bristol werde zudem in den kommenden Jahren mindestens weitere 30 Mio. USD Forschungsgelder beisteuern. Charttechnisch betrachtet habe der Kurs mit dem Ausbruch aus der monatelangen Tradingrange zwischen 5 und 6 USD bereits das Signal für eine Rallye gegeben.

Die Experten vom "Global Biotech Investing" raten den Anlegern die Lexicon Genetics-Aktie zu kaufen.

[meislo]

7,58 plus 8,X%, hohe umsätze und morgen die konferenz

Ich denke mal das die 10 dollar-marke bald erklommen ist

gruss meislo

[meislo]

geschlossen bei 7,69 nachbörslich bei 8 dollar

[Tanzbaerli]

Hi Meislo!

Bin froh daß ich mein Geron-Kapital derzeit hier angelegt habe ... mal sehen wie es weitergeht!

Übrigens ... Bei deinen Tip Net ag tut sich ja gar nix! Drinnenbleiben ????

Grüße ... Bärli

[meislo]

Hi tanzbaerli

in der tat netag läuft nicht gut. am 14.2.2004 kommen quartalszahlen aber ich denke dass es nicht mehr solange dauert bis auch netag fahrt aufnimmt. ich für meinen teil bleibe jedenfalls investiert.

gruss meislo

präsentation nicht verpassen!!

http://www.lexicon-genetics.com/

[Tanzbaerli]

Heute lief die Net AG ja (bisher) ganz gut aber irgendwie steckt der Wert fest!

Aber zurück du lexicon. Startete ja gestern voll durch und ich denke daß vor einer eventuellen Korrektur es noch weiter geht.

In diesen Sinne ... gleich gets los an der Nasdaq!

.... Bärli

[meislo]

Hi tanzbaerli

netag 2,20
geron 11,80 dollar

geron unter hohen umsätzen, an der aktie muss einfach was dran sein!!!


gruss meislo

[Gluewuermchen]

Bin auch seit heut in Lexi investiert!

Bin von dem Unternehmen überzeugt!

Habe auch in combimatrix-CBMX investiert,vor ein paar Tagen,läuft auch super,auch eine sehr interessante Company!

gruss glüh

[Tanzbaerli]

Hi WÜrmchen!

Denke auch daß bei Lexicon noch einiges kommen wird! Bin in dem Wert zum Glück auch rechtzeitig reingegangen um mich schon über erste Gewinne zu freuen.

Lexicon ist ja nun wirklich im "Global Biotech Investing" einer der neuen Depotwerte; daneben auch Geron das mich aber im letzten helben Jahr enttäuschte sodaß ich mir einen Neueinstieg dort gründlich überlegen werde.

Ansonsten bin ich derzeit voll investiert; eventuell wäre nach dem Amazon Zahlen eine Umschichtung zu überlegen.

Dann schaun wir mal ob wir zu den 1 % gehören die wirklich an der Börse reich werden ... bisher sieht es bei mir trotz spektakulärer Einzelerfolge nicht danach aus

... Bärli

[Tanzbaerli]

Gestern ein gewaltiger Einbruch!
Nachkaufgelegenheit!
Warum???

Habe mir gerade die Präsentation von der Konferenz gestern angesehen; die list sich ja toll und gibt viel Hoffnung für die Zukunft. Da scheint sich wirklich was anzubahnen!

Sie rechnen damit daß mindestens 4 Drogen aus der Cooperation mit Bristol-Myers auf den Markt kommen und alleine mit 450 Millonen Dollar Einnahmen daraus im Vorfeld wobei die Einnahmen aus Produktverkäufen noch gar nicht mitgerechnet sind!

Möge es so kommen .... Bärli

[Tanzbaerli]

Neue Hochs: Ziel ist Verdreifachung! (02.02.2004)

Schon mehrfach hat „Global Biotech Investing“ dieses Genforschungsunternehmens vorgestellt. Die Experten haben den Wert selbst im Musterdepot. Aufgenommen bei 5,65 Euro, steht der Kurs bei aktuell 6,35 Euro. Das Kursziel: kurzfristig 12 Euro, mittelfristig 24 Euro: Doch nicht nur die spannenden News verhelfen Lexicon Genetics (WKN 936717) zu steigenden Kursen. Auch die Charttechnik dürfte weiter erstarken, nachdem der Ausbruch geschafft wurde. Während „Global Biotech Investing“ empfiehlt, keine Aktie aus der Hand zu geben, empfehlen wir die Anpassung des Stopp-loss-Kurses.

Quelle: www.boersenwelt.de

[Ruckizucki]

Mittlerweile siehts ja nicht mehr so gut aus.

[Tanzbaerli]

Ich denke daß da schon noch ein Schub kommen könnte und wenn nicht .... mein Stop-Loss liegt bei 7 Dollar (will ja die schönen Gewinne mitnehmen)!

... Bärli

[Tanzbaerli]

THE WOODLANDS, Texas, Feb. 19 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated , a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease, today reported financial results for the three months and year ended December 31, 2003.

Revenues: Lexicon``s revenues for the three months ended December 31, 2003 increased 35 percent to $13.7 million from $10.1 million for the corresponding period in 2002. The increase was primarily attributable to the completion of the first performance milestone under a drug discovery collaboration with Genentech, Inc. For the year ended December 31, 2003, revenues increased by 22 percent to $42.8 million from $35.2 million in 2002.

Research and Development Expenses: Research and development expenses for the three months ended December 31, 2003 increased six percent to $20.3 million from $19.2 million for the corresponding period in 2002. The increase primarily reflects the expansion of the Company``s drug discovery programs and medicinal chemistry operations. For the year ended December 31, 2003, research and development expenses increased ten percent to $82.2 million from $74.9 million in 2002. Research and development expenses included non-cash, stock-based compensation expense of $1.2 million and $1.3 million for the three months ended December 31, 2003 and 2002, respectively, and $5.0 million and $5.2 million for the years ended December 31, 2003 and 2002, respectively.

General and Administrative Expenses: General and administrative expenses for the three months ended December 31, 2003 increased four percent to $5.7 million from $5.5 million for the corresponding period in 2002. For the year ended December 31, 2003, general and administrative expenses were $23.2 million, unchanged from 2002. General and administrative expenses included non-cash, stock-based compensation expense of $1.2 million and $1.3 million for the three months ended December 31, 2003 and 2002, respectively, and $5.1 million for each of the years ended December 31, 2003 and 2002.

Net Loss: Net loss before cumulative effect of a change in accounting principle for the three months ended December 31, 2003 decreased to $11.8 million from $13.9 million for the corresponding period in 2002. Net loss before cumulative effect of a change in accounting principle for the year ended December 31, 2003 increased to $61.1 million from $59.7 million for the corresponding period in 2002. Net loss per share before cumulative effect of a change in accounting principle for the three months and year ended December 31, 2003 was $0.19 and $1.08, respectively, compared to $0.26 and $1.14, respectively, for the corresponding periods in 2002. Net loss before cumulative effect of a change in accounting principle includes non-cash, stock-based compensation expense of $2.5 million and $2.6 million for the three months ended December 31, 2003 and 2002, respectively, and $10.1 million and $10.3 million for the years ended December 31, 2003 and 2002, respectively.

The cumulative effect is a one time, non-cash charge of $3.1 million related to the adoption of FIN 46, "Consolidation of Variable Interest Entities." This charge represents accumulated depreciation through December 31, 2003 on the properties under Lexicon``s synthetic lease. The Company consolidated its synthetic lease on December 31, 2003 in accordance with FIN 46. As a result of FIN 46, Lexicon``s balance sheet reflects additional property and equipment of $54.8 million less the accumulated depreciation, $52.3 million as long-term debt and $2.5 million as other long- term liabilities.

Net loss for the three months ended December 31, 2003 increased to $14.9 million from a net loss of $13.9 million in the corresponding period of 2002. For the year ended December 31, 2003, net loss increased to $64.2 million compared to a net loss of $59.7 million in 2002. Net loss per share for the three months and year ended December 31, 2003 was $0.24 and $1.13, respectively, compared to $0.26 and $1.14, respectively, for the corresponding periods in 2002. Net loss includes non-cash, stock-based compensation expense and the cumulative effect of a change in accounting principle.

Cash and Investments: As of December 31, 2003, Lexicon had $161.0 million in cash and investments, including restricted cash and investments, compared to $133.6 million as of September 30, 2003 and $123.1 million as of December 31, 2002. The increase in cash and investments from September 30, 2003 to December 31, 2003 was primarily attributable to the receipt of a $36.0 million upfront payment related to Lexicon``s neuroscience alliance for drug development with Bristol-Myers Squibb, which was established in December 2003. Restricted cash and investments were $57.5 million at December 31, 2003 and September 30, 2003 and $57.7 million at December 31, 2002.

"We are pleased with our financial performance in 2003. We realized our eighth consecutive year of revenue growth, continued to carefully control expenses and supplemented our strong cash position through corporate alliances and capital raising activities," said Julia P. Gregory, executive vice president, corporate development and chief financial officer of Lexicon. "Our solid balance sheet has enabled us to rapidly advance our drug discovery activities."

Year 2003 Highlights

"In 2003, Lexicon made significant progress on all fronts, with many notable scientific and corporate achievements," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Lexicon. "Forty novel drug discovery programs have been harvested from our Genome5000(TM) program, which is now 30% complete. In addition, we achieved the first performance milestone under our drug discovery alliance with Genentech, Inc. and formed a broad drug discovery alliance with Bristol-Myers Squibb Company in the field of neuroscience. We believe our ability to systematically determine the physiological function of human genes provides Lexicon and its collaborators with a competitive advantage in the race to discover future breakthrough therapeutics."

Lexicon``s key business and scientific accomplishments in 2003 include:

Established neuroscience alliance with Bristol-Myers Squibb: Lexicon Genetics and Bristol-Myers Squibb Company formed a broad alliance for drug discovery, development and commercialization in the neuroscience field in December 2003. The alliance is designed to accelerate the discovery and development of breakthrough therapies to address significant, unmet medical needs in psychiatry and neurology. Lexicon will contribute 13 drug discovery programs from its current neuroscience pipeline to the alliance. In addition, the alliance will have exclusive access to future neuroscience discoveries from Lexicon``s Genome5000 program for drug development. Lexicon received an upfront payment of $36 million from Bristol-Myers Squibb and will receive a minimum of $30 million in research funding over the initial, three-year term of the agreement. Bristol-Myers Squibb has the option to extend the discovery portion of the alliance for two years in exchange for further committed research funding of up to $50 million. Lexicon will receive additional cash payments for exceeding specified research productivity levels. Lexicon will also receive clinical and regulatory milestone payments and royalties for each novel drug target for which Bristol-Myers Squibb develops a drug under the alliance.

Achieved first performance milestone in Genentech alliance: Lexicon announced the achievement of the first performance milestone under its drug discovery alliance with Genentech, Inc. Lexicon established this alliance with Genentech in December 2002 to discover novel therapeutic proteins and antibody targets. Under the alliance agreement, Lexicon is using its target validation technologies to discover the functions of secreted proteins and potential antibody targets identified through Genentech``s drug discovery research.

Completion of a common stock offering: Lexicon completed a public offering of 10,240,000 shares of common stock at $5.25 per share in the third quarter of 2003. Net proceeds to the Company from the offering were $50.1 million.

Continued record of revenue growth: Lexicon achieved $42.8 million in annual revenues in 2003, marking the Company``s eighth consecutive year of revenue growth.

Initiated more than 40 drug discovery programs: Lexicon``s Genome5000 program for drug discovery has yielded more than 40 drug discovery programs in the fields of diabetes, obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. In its Genome5000 program, Lexicon is analyzing 5,000 genes using its proprietary gene knockout technologies and its extensive physiological and behavioral analyses to discover novel drug targets from the human genome. To date, Lexicon has completed the analysis of more than 1,500 genes.

Established ophthalmic disease as an area of therapeutic focus: Lexicon``s physiology-based analysis of gene function includes non-invasive tests to identify targets with potential for the development of drugs to treat diseases and conditions of the eye. Lexicon has discovered potential ophthalmic uses for several targets and will be evaluating their efficacy in areas such as glaucoma, macular degeneration and retinopathy. Lexicon believes that the combination of functional genomics with the assessment of the eye gives the Company unique opportunities for the discovery of drugs to address major unmet medical needs in the field of ophthalmology.

Publication of hypertension discovery: Lexicon published a study identifying a novel gene target for the control of high blood pressure with a direct link to human hypertension in the Proceedings of the National Academy of Science in November 2003. The paper was entitled "Wnk1 kinase deficiency lowers blood pressure in mice: A gene-trap screen to identify potential targets for therapeutic intervention." Lexicon holds the patent on the human WNK1 gene sequence and has filed patent applications claiming its medical use as a target to develop new therapeutics for high blood pressure.

Retrospective evaluation of the targets of the 100 best-selling drugs: Lexicon published in the January 2003 issue of Nature Reviews Drug Discovery a retrospective evaluation of the targets of the 100 best-selling drugs of 2001 as modeled by mouse knockout phenotypes. The article concluded that, in most cases, there is a direct correlation between the knockout and the therapeutic effect of the drug. The 100 best-selling drugs of 2001 modulate a total of 43 host targets. Of those targets studied in mouse knockouts, eighty-five percent were informative with respect to the physiological function and pharmaceutical utility of the target.

Key intellectual property developments: Lexicon announced the issuance of a new U.S. patent that broadly covers the most widely-practiced methods of producing genetically-engineered knockout mice by gene targeting. The issuance of this patent fortifies Lexicon``s intellectual property position in the fields of gene targeting by homologous recombination and gene knockout technology. As a result of this patent, and a new gene targeting patent issued in February 2004, Lexicon has broad, exclusive rights in certain fields under eight issued U.S. patents covering aspects of gene targeting. The technologies covered by these eight patents are widely used in the pharmaceutical and biotechnology industries for drug discovery.

Lexicon Conference Call:

Dr. Arthur T. Sands, president and chief executive officer, and Julia P. Gregory, executive vice president, corporate development and chief financial officer, will review Lexicon``s operating highlights and financial results for the three months and year ended December 31, 2003 and discuss the Company``s guidance for 2004 in a telephone conference call at 11:00 a.m. EST today, February 19, 2004.

Conference call participants may dial: 800/500-0311 (domestic USA), 719/457-2698 (international). Pass code for all callers: 404648.

The audio web cast can be heard by logging on to http://www.lexicon-genetics.com/ . It will be archived and available for review through February 24, 2004.

[Tanzbaerli]

Tja ... leider (oder Gott sei dank) hat mein Stop-Loss gegriffen. Lexicon ist (unverständlicherweise) im sauberen Abwärtstrend gelandet.

Ich beobachte weiter und werde bei einer Trendwende wieder einsteigen da ich an die Firma eigentlich glaube!

Außer mir scheint sowieso niemand investiert zu sein

... Bärli

[Ruckizucki]

Doch - ich

Bin auch etwas enttäuscht über den momentanen Kursverlauf, da die zahlen doch ziemlich gut ausgefallen sind. Aber an der Börse gehts nun mal knall hart zur Sache. vermutlich wird der Kurs gedrückt, um dann billiger wieder einzusteigen. Fundamental jedenfalls sehe ich keinen Grund für diesen Kursverfall.

[Tanzbaerli]

ICh sehe das genauso aber ich wollte einfach mal den Gewinn einstreichen. Nun hoffe ich auf Kurse unter 6 Dollar um dann eventuell wieder reinzugehen.

Wenn die Aktie nicht zurückkommt ... naja eine Chance mehr verpasst!

... Bärli

[Tanzbaerli]

Wenn die 7 Dollar nicht bald (in den nächsten 2 tagen) wieder erreicht werden, dann bleubt der Abwärtstrend intakt und bald gibt es Lexicon um 6 Dollar (was ich mir wünsche da ich ja wieder ein will


... Bärli

[Tanzbaerli]

Kamen ja schneller als erwartet die 7$. Sollten wir heute dort nicht abprallen und wieder runter gehen dann ... wäre charttechnisch wieder ein Kauf angesagt und mein Ausstieg war falsch!

Sollten wir abprallen und im trendkanal bis auf 6$ runtergehen dann heisst es abwarten um mit dem Wiedereinstieg bis zum Bruch des Abwärtstrnds warten.

Mann ... rede ich gescheit daher obwohl ich keine Ahnung habe!

... Bärli

[Tanzbaerli]

Lexicon hängt an 7$ !!!

Ich warte auf Chartsignal ... gehen drüber wäre es ein Kaufsignal!

Leider kann sich Lexicon nicht entscheiden!

... meint das Bärli

[Tanzbaerli]

Weiterhin ist Lexikon Genetics im abwärts Trendkanal und folgt ihm vorbildlich. Charttechnisch ist mit Kursen unter 6 Dollar zu rechnen!

Ich werde beim Break wieder einsteiegn ... dies ist aber noch in keiner Weise sichtbar. Der Boden dürfte allerdings zwischen 5 und 6 Dollar sein!

Das mein das Bärli!

[Tanzbaerli]

Lexicon läuft vorbildlich in den erwarteten Kanal zwischen 5 und 6 Dollar rein. Der steile Abwärtstrend ist voll intakt!

Ich werde bei 5 Dollar vermutlich wieder dabei sein wobei die Gefahr besteht daß die 5 Dollar nicht erreicht werden. Ein Einstieg vor einer Trendwende ist jedoch riskant und nur für Mutige zu empfehlen.

Es könnte ja auch noch weiter runter gehen ... !

Sollte die Wende jedoch kommen scheinen mindestens 50 Prozent Gewinn auf Sicht von ein paar Monaten vorprogrammiert!

Das meint das Bärli!

[Tanzbaerli]

Es ist verdächtig ruhig um Lexicon Genetics!

Da ich weiter fundamental von der Akrie überzeugt bin und charttechnisch das Ende des Abwärtstrends erreicht ist bin ich wieder drin.

Sollte der Wert wieder unter 6$ fallen dann war ich vermutlich zu bald dran .... ansonsten rechne ich mit dem vorläufigen Kursziel von 9$.

Schaun wir mal ob ich richtig liege!

.... Bärli

[Tanzbaerli]

Noch wurde meine Entscheidung wieder einzusteigen weder bestätigt noch hat sie sich als falsch herausgestellt!

War der gestrige Anstieg ein Start zu neuen Höhen?
Man wird sehen!

Schon schön hier immer Selbstgespräche zu führen ... sollte wohl mehr auf Mainstream Aktien setzen!

.... Bärli

[Tanzbaerli]

THE WOODLANDS, Texas, April 19 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated will hold a conference call to discuss its first quarter 2004 financial results at 11:00 a.m. EDT on Thursday, April 29, 2004. Lexicon will release its results on April 29, 2004 before the market opens.

Dr. Arthur T. Sands, president and chief executive officer, and Julia P. Gregory, executive vice president, corporate development and chief financial officer, will host the conference call. They will review Lexicon``s operating highlights and financial results for the three months ended March 31, 2004 and will discuss the company``s expectations for the second quarter.

Conference call participants may dial: 800/930-1344 (domestic USA), 312/461-0644 (international). Pass code for all callers: 648215. Investors can access http://www.lexicon-genetics.com/ to listen to a live webcast of the call. The webcast will be archived and available for review through May 4, 2004.

[Tanzbaerli]

Da sonst keiner da ist plaudere ich eben weiter mit mir selber!

Scheint so als ob die Trendwende funktioniert hat und ich den idealen Wiedereinstiegszeitpunkt erwischt habe.

Naja ... wenigstens einmal bei einer Aktie!

Ansonsten ist es ja relativ ruhig um Lexicon. Ob die alten Kursziele von 24 Dollar noch gelten?

Was solls ... lassen wir mal die Gewinne laufen ...

.... Bärli

[bernie55]

hallo tanzbaerli,
ich wollte dir nur sagen, dass ich sehr gerne deine "monologe" und kurzanalysen lese.....
ich bin in vielen biotechs investiert und nicht immer "online".....deshalb, lieber tanzbaerli , mach ruhig weiter....ich bin immer in deiner nähe


grüße bernie55

[Tanzbaerli]

NEW YORK, April 23 (New Ratings) - Analysts at WR Hambrecht initiate coverage of Lexicon Genetics (LEXG.NAS) with a "buy" rating. The 12-month target price is set to $10.

Shares of Lexicon Genetics, a biopharmaceutical company, are currently trading at $6.82.

According to WR Hambrecht `s research note published yesterday, the company uses proprietary gene knockout technology to discover genes that exhibit favorable therapeutic profiles. Lexicon Genetics has been systematically culling 5000 pharmaceutically important genes to discover several targets. The company has the potential to discover over 25 new and important targets every year, the analysts say. The company benefits from its several strategic collaborations and alliances with leading pharmaceutical and biotechnology companies, the analysts mention. These partnerships provide financial support and future leverage during the company`s internal research, WR Hambrecht says. Lexicon Genetics also benefits from its capability to develop breakthrough drugs and antibodies for its targets, the analysts mention.

The analysts express their optimism regarding the company`s performance in the forthcoming years. WR Hambrecht believes that Lexicon Genetics would benefit substantially from its unique technology in the near future.

The EPS estimates for 2004, 2005 and 2006 are $0.85, -$0.75 and -$0.80, respectively.

WR Hambrecht initiates coverage of Lexicon Genetics with a "buy" rating

[bernie55]

....tja mit 10$ wären wir doch schon zufrieden, oder ??

mfg bernie55

[Tanzbaerli]

Lexicon Genetics Reports 2004 First Quarter Financial Results

THE WOODLANDS, Texas, April 29 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated , a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease, today reported financial results for the three months ended March 31, 2004.

Revenues: Lexicon``s revenues for the three months ended March 31, 2004 increased 46 percent to $11.8 million from $8.1 million for the corresponding period in 2003. The increase was primarily attributable to revenue recognized under Lexicon``s neuroscience alliance for drug development with Bristol-Myers Squibb Company.

Research and Development Expenses: Research and development expenses for the three months ended March 31, 2004 increased 13 percent to $22.4 million from $19.8 million for the corresponding period in 2003. The increase primarily reflects the continued advancement of Lexicon``s drug discovery programs. Research and development expenses included non-cash, stock-based compensation expense of $0.4 million and $1.3 million for the three months ended March 31, 2004 and 2003, respectively.

General and Administrative Expenses: General and administrative expenses for the three months ended March 31, 2004 decreased 13 percent to $5.0 million from $5.8 million for the corresponding period in 2003. General and administrative expenses included non-cash, stock-based compensation expense of $0.4 million and $1.3 million for the three months ended March 31, 2004 and 2003, respectively.

Net Loss: Net loss for the three months ended March 31, 2004 decreased to $15.5 million, or $0.25 per share, from a net loss of $17.1 million, or $0.33 per share, in the corresponding period in 2003.

Cash and Investments: As of March 31, 2004, Lexicon had $145.4 million in cash and investments, including restricted cash and investments, compared to $161.0 million as of December 31, 2003. Restricted cash and investments were $57.5 million on both such dates. Lexicon``s cash and investments and restricted cash and investments changed subsequent to March 31, 2004 as a result of the refinancing of the Company``s synthetic lease, as described in "Subsequent Event" below.

Subsequent Event: On April 21, 2004, Lexicon refinanced the $54.8 million synthetic lease of its headquarters and research facility in The Woodlands, Texas with a $34.0 million conventional mortgage and repaid the balance of its obligations under the lease arrangement. The mortgage has a ten-year term with a 20-year amortization and bears a fixed interest rate of 8.23%. As a result of the refinancing, Lexicon``s long-term debt and other long-term liabilities decreased by $21.4 million and its cash and investments decreased by approximately $22.4 million. Importantly, the transaction eliminated all restrictions on the cash and investments that had secured Lexicon``s obligations under the synthetic lease, leaving the Company with a net increase of $34.5 million in its unrestricted cash and investment balances. A total of $0.6 million remains in restricted investments.

"Restructuring the financing to own our unique, state-of-the-art facility in The Woodlands enables us to control one of our key strategic assets in the race for novel drug discoveries from the human genome," said Julia P. Gregory, executive vice president, corporate development and chief financial officer of Lexicon. "The transaction unrestricts all of our cash, thereby increasing our financial flexibility and extending our ability to fund our drug discovery and development operations, based on current expectations, through about the next three years. We were pleased to refinance our facility while in a relatively low interest rate environment."

First Quarter 2004 Highlights

"The productivity of Lexicon``s drug discovery engine has persisted in 2004. We are continuing to identify exciting, novel drug targets using our industrialized gene knockout technology and our phenotypic and behavioral screens and are on track to attain our goal of 25 to 30 additional drug discovery programs this year," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Lexicon. "In addition, we are encouraged by the pre-clinical progress of several of our lead small molecule and antibody drug development programs."

Lexicon``s key business and scientific accomplishments in first quarter 2004 include:

Novel discoveries from Genome5000(TM) program: Lexicon``s Genome5000 program for drug discovery continued to yield novel drug discovery programs. Lexicon has harvested more than 40 drug discovery programs from its Genome5000 program in the fields of diabetes, obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. In its Genome5000 program, Lexicon is analyzing 5,000 genes using its proprietary gene knockout technologies and its extensive physiological and behavioral analyses to discover novel drug targets from the human genome. To date, Lexicon has completed the analysis of more than a third of these genes.

Key intellectual property developments: Lexicon``s intellectual property position in the gene targeting and gene knockout fields was further fortified by the issuance of a new U.S. patent that broadly covers a key technology used in gene targeting. The patented technology encompasses a variety of methods of selecting desired genetic manipulations made by gene targeting, and specifically includes methods that are sometimes referred to as "positive- positive" selection. As a result of this patent, Lexicon has broad, exclusive rights in certain fields under eight issued U.S. patents covering aspects of gene targeting. The technologies covered by these eight patents are widely used in the pharmaceutical and biotechnology industries.

[biotech_nett]

Hallo Tanzbaerli, vielen Dank für die vielen interessanten Mitteilungen. Bin auch in vielen Bios investiert und sehe Lexicon als ein fundamentales und sehr aussichtsreiches Investment. Glaube die Position sollte noch etwas aufgestockt werden um in einem Jahr dicke Früchte zu ernten.

biotech_nett

[Clouse]

hey, wo seid ihr alle ?
LEXG steigt und keiner meldet sich. Weiß jemand mehr, gibt es neue Infos ?
Clouse

[Tanzbaerli]

Schön so!

Wer meinen Anmerkungen gefolgt ist kann sich über 20% Gewinn freuen.

Ich denke daß Lexicon sowohl von der guten Stimmung wie von der Unterbewertung mehr als Andere profitiert.

Für mich erscheint ein Erklimmen der alten Höchststände )über 8$) als sicher bevor eventuell eine Sommerpause eingelegt wird!

Bleibt einfach drinnen!

Schönes Wochenende

Und nun ein heißer Tip!

Mit Cardero Resources konnte man in den letzten paar Tagen 40 Prozent machen!! Ein Anfang der mindestens 1000% die kommen werden oder des Totalverlustes! No risk no fun !!!

[biotech_nett]

Also,

ich muss mal was sagen hier, der biotech-investor gibt schon lange die Kaufempfehlung für lexicon, nachdem sie aus dem "musterdepot" flogen kaufte ich, seitdem tut sich nicht viel, die kursziele gelten noch . Die Aktie bewegt sich kaum und ich überlege ob ich noch mehr kaufe, doch vielleicht lieber meine besten die Hemispherx, leider sind sie auch aus alten höhen zurück vielleicht doch lieber ID-Biomedical nachkaufen?? charttechnisch dürften sie ja irgendwann mal zur 21 € gehen

Grüsse und viel Spass bei den Bios

[Tanzbaerli]

Die 8$ scheinen schwer zu überwinden sein. Denke daß nun erstmal eine Pause eingelegt wird.

Ich traue den Wert einen Rückfall genauso wie einen steilen Anstieg zu. Ob die euphorischen Kursziele von 12 und dann 24$ jedoch erreicht werden ... wir werden sehen!

... Bärli

[Tanzbaerli]

Tja ... hab durch Urlaub den Ausstieg verpasst!?

Wie für den Anstieg gibts auch für den Rückfall keine wirklich fundamentalen Gründe.

So geshen müsste die Trendwende eigentlich kommen ....

... philosophiert das Bärli

[Tanzbaerli]

Lexicon Genetics, Takeda Pharma In Hypertension Alliance


07-28-04 03:09 AM EST
THE WOODLANDS, Texas -(Dow Jones)- Lexicon Genetics Inc. (LEXG) and Takeda Pharmaceutical Co. (4502.TO) formed a collaboration to develop drugs for high blood pressure.

In a press release Wednesday, Lexicon said it will receive a $12 million upfront payment from Takeda for the initial, three-year term of the agreement, and Takeda will have exclusive access to all drug targets from Lexicon`s Genome5000 program that control blood pressure.

In its Genome5000 program, Lexicon is analyzing 5,000 genes with its proprietary gene knockout technology to discover novel drug targets from the human genome.

Under the collaboration, Takeda will be responsible for the screening, medicinal chemistry, preclinical and clinical development and commercialization of drugs directed against Lexicon`s novel blood pressure targets, and will bear all related costs.

Takeda has the option to extend the initial three-year discovery portion of the alliance for an additional two years in exchange for further committed funding.

Takeda will also make research milestone payments to Lexicon for each target selected for therapeutic development, as well as clinical development and product launch milestone payments for each product commercialized.

Lexicon said it will also earn royalties on worldwide sales of drugs marketed by Takeda.

Lexicon Genetics is a biopharmaceutical company, and Takeda is an Osaka, Japan-based pharmaceutical company.

[Tanzbaerli]

Rating-Update:

Die Analysten vom Investmenthaus Punk Ziegel & Co. stufen die Aktie von Lexicon Genetics (ISIN US5288721047/ WKN 936717) unverändert mit "buy" ein. Das Kursziel werde bei 24 USD gesehen.

...............................................

Irgendwie schreiben die "Punker" seit 1 Jahr dasselbe!

... Bärli

[biotech_nett]

Hallo Bärli,

was mich nervt sind einfach immer diese absolut überzogenen Kursziele dieser "Spezialisten" - #
meistens sind die Kursziele wie eine Fatamorgana, sichtbar doch nie zu erreichen ...

Ich empfehle momentan eher den Verkauf dieser Lexicon und dafür die Investition in Hemispherx - sieht einfach viel besser aus uns ist nicht so ausgelutscht von den Analysten

... und ich kaufe wieder mehr Hemis
... und warte bis die auf 6 stehen

cu

[Tanzbaerli]

Tja ... jetzt bleibe ich drinnen da ich wieder auf ein Hochgehen auf mindestens 8$ setze. Ob bei Lexicon große Sprunge drin sind bezweifle ich auch etwas ... ist aber auch nicht so riskant wie andere Werte.

Ob man z.Bsp. bei Geron wieder reingehen sollte?

... Bärli

[Tanzbaerli]

Stop Loss hat gegriffen ... bin also auch raus. Ich warte nun auf die charttechnische Wende!

Biotech läuft derzeit einfach schlecht!

... Bärli

[Tanzbaerli]

Wie bereits angedeutet sehe ich Lexicon Genetics als Wert bei dem man die charttechnischen Wendemarken beachten sollte.

Das hat in letzter Zeit Gewinne gebracht. Leider habe ich auch den letzten Austieg verpasst und bin erst knapp vor der Wende raus.

Seit gestern aber wieder drin und ... hat sich schon bezahlt gemacht.

Warten wir (ich) auf die nächste Wende!

... Bärli

[biotech_nett]

Bärli,
Geron habe sie doch auch mal empfohlen, ich habe den Bio-Investor abbestellt. - ID steigen und steigen, vorallem nachdem Sie auch noch die Impfstoffe produzieren - doch meine Lieblinge sind einfach die Hemispherx!!!

Daneben noch ein paar Trinity reingelegt, sehen sehr positiv aus und liefern super Ergebnisse nächstes Jahr, langfristig denken, auch mit den Lexicon???


... und viel Glück für alle ...

[kurttilly]

Moneytalk Radio

Heute Kos Pharma - Kaufen!

Heute Vossloh will bei Alstom kaufen

Heute Lexicon Genetics erhält Meilenstein



Kennt jemand die Meldung von Lexicon Genetics ???

mfg

kurttilly

[kurttilly]

Hallo Leute!

Ist denn niemand mehr an Lexicon interessiert????

- der Kurs tümpelt so vor sich hin

- keine Meldungen mehr


..... was ist los mit Lexicon Genetics ????


mfg

kurttilly

[Tanzbaerli]

Ich (Eröffner des Threads) habe das Interesse verloren.

Der Kurs bewegt sich eigentlich seit Jahren nicht wirklich vom Fleck.

Die Change zu verdienen lag darin zum richtigen Zeitpunkt ein- bzw. auszusteigen. Dies gelang mir aber auch nur einmal und einmal war ich voll daneben!

Habe derzeit nicht vor wieder reinzugehen!

Allen viel Erfolg ... Bärli

[wohinistmeinGeld]

ich hab schon so lange nicht mehr nach der Aktie geschaut, daß ich ganz vergessen habe was die eigentlich machen.
Ich lass sie halt mal liegen und habe dann hoffentlich in ein paar Jahren 1000%.

[bernie55]

Roche Renews Internal Research License for Patented Gene Targeting Technology From Lexicon Genetics

THE WOODLANDS, Texas, Dec. 21 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - News) announced today that Roche Palo Alto LLC has renewed its license agreement for non-exclusive rights under patents controlled by Lexicon covering gene targeting technologies for the generation of knockout mice. The renewed license will provide Roche with continued rights under patents covering the technologies frequently referred to as "isogenic DNA" and "positive-negative selection" to generate and use knockout mice in its internal drug discovery research. Financial terms of the agreement were not disclosed.


Lexicon Genetics Awarded Biodefense Grant From the United States Army

THE WOODLANDS, Texas, Dec. 22 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - News) announced today that it was awarded a grant from the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) for the discovery of novel drug targets that could provide resistance to ricin poisoning. Lexicon will receive $1.9 million in funding for the one-year initial term of the grant.



nachzulesen unter : http://www.uptotrade.de/ - - BIOTECHNEWS USA

grüße bernie55

[bernie55]

Lexicon Genetics Discovers Potential New Therapies For Cancer and Bleeding Disorders

THE WOODLANDS, Texas, Jan. 10 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - News) announced today that it has advanced two of its drug discovery programs into preclinical development in preparation for investigational new drug (IND) applications. The first, LX-1521, is a small molecule compound to be developed as a potential cancer treatment. The second, LX-5431, is a protein to be developed as a potential biotherapeutic for thrombocytopenia, a condition that results in bleeding disorders. The functions of the targets of both potential therapies were discovered in Lexicon`s Genome5000(TM) gene knockout program. This program has produced more than 60 drug discovery programs to date.
ADVERTISEMENT


LX-1521

LX-1521 is a novel small molecule compound with potential for treating solid tumor cancers. LX-1521 works by blocking the cell cycle prior to cell division, resulting in cancer cell death through apoptosis. When administered orally to mouse models of human cancer, LX-1521 demonstrates significant anti- tumor activity in vivo while exhibiting no apparent gross toxicity. In vitro, the compound inhibits growth of more than 20 human tumor cell lines derived from multiple types of cancer. Potential uses of LX-1521 as a cancer therapy include the treatment of breast, prostate, lung, colon, ovarian, renal and pancreatic cancer, as well as melanoma.

LX-1521 was discovered in Lexicon`s LG152 kinase target program. Lexicon found that this kinase plays a role in cell proliferation when cells from knockout mice lacking the LG152 gene exhibited a decreased rate of growth. Lexicon then demonstrated that cells overexpressing LG152 form tumors in nude mice, indicating that LG152 can function as an oncogene. LX-1521 is one of a number of potent inhibitors of LG152 created in Lexicon`s medicinal chemistry program. The mechanism of action of LX-1521 likely also includes inhibition of other kinase targets, a characteristic of many small molecule kinase inhibitors. Lexicon expects to file an IND for LX-1521 by the end of 2005 and commence a Phase 1 clinical trial for the compound shortly thereafter.

"Our preclinical research to date indicates that LX-1521 effectively inhibits tumor growth in animal models without the toxicity typical of many current chemotherapy drugs," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Lexicon. "Based on our current understanding of LX-1521`s mechanism of action, we believe it has potential as a targeted therapy for cancer."

All cancers involve the malfunction of genes that control cell growth and division. According to the American Cancer Society, approximately one out of every two American men and one out of every three American women will have some type of cancer at some point during their lifetime. This year, more than 500,000 Americans are expected to die of cancer and more than 1.3 million new cancer cases are expected to be diagnosed in the United States. Prostate cancer is the most prevalent cancer in men, representing 33% of new cancer cases. In women, breast cancer is most prevalent, representing 32% of new cancer diagnoses.

LX-5431

LX-5431 is a novel recombinant human protein with the potential for treating thrombocytopenia, a disorder characterized by a lack of platelets in the blood that can lead to severe bleeding. LX-5431 has been demonstrated in ex vivo bone marrow culture to stimulate production of platelet forming cells called megakaryocytes. LX-5431 may have potential for treating thrombocytopenia resulting from chemotherapy, leukemia, autoimmune disease and other conditions.

LX-5431 was identified in Lexicon`s LG543 secreted protein program. Lexicon discovered that this secreted protein is a growth factor required for platelet production when the LG543 gene knockout was observed to have decreased platelet concentration in the blood. The LG543 gene knockout also exhibited a decreased percentage of megakaryocytes in the bone marrow and spleen. Lexicon`s scientists cloned the human gene and produced the recombinant human protein. During 2005, Lexicon expects to develop scale-up methodologies to produce LX-5431 in quantities required for preclinical and early clinical development.

Thrombocytopenia can result from a variety of conditions including exposure to chemotherapeutic agents, leukemia, bone marrow transplantion and autoimmune disease. Chemotherapy, in particular, can greatly reduce platelet levels, and chemotherapy patients often require blood transfusions to protect against excessive bleeding. Each year in the United States, approximately eight million units of platelets are transfused into patients to reduce the risk of severe bleeding (New England Journal of Medicine, March 1998, pages 746-754).

"Discovery of a drug to increase platelet production has been a long standing objective of the biopharmaceutical industry," said Brian P. Zambrowicz, Ph.D., executive vice president of research at Lexicon. "Our data suggest that LX-5431 offers promise in meeting this major medical goal."

The LG152 and LG543 drug targets were discovered in Lexicon`s Genome5000 program. In this program, Lexicon is using its proprietary gene knockout technology to rapidly discover the physiological and behavioral functions of 5,000 of the most pharmaceutically important genes in the human genome. To date, Lexicon has completed the analysis of more than 2,000 of these genes and has harvested more than 60 drug discovery programs. In addition to cancer and immune systems disorders, Lexicon has drug discovery programs in the fields of diabetes and obesity, cardiovascular disease, ophthalmic disease and psychiatric and neurological disorders.

Dr. Sands will discuss LX-1521 and LX-5431 during his presentation at the 23rd Annual JPMorgan Healthcare Conference at The Westin St. Francis Hotel in San Francisco on Wednesday, January 12, 2005 at 4:00 p.m. Pacific Time. A live audio webcast of Dr. Sands` presentation may be accessed on Lexicon`s corporate website at http://www.lexicon-genetics.com. An archived version of the webcast will be available on the website through January 20, 2005.

About Lexicon Genetics

Lexicon Genetics is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. Lexicon is systematically discovering the physiological and behavioral functions of genes to identify potential points of therapeutic intervention, or drug targets. Lexicon makes these discoveries using its proprietary gene knockout technology to model the physiological effects that could be expected from prospective drugs directed against novel targets. The Company has advanced knockout-validated targets into drug discovery programs in six therapeutic areas: diabetes and obesity, cardiovascular disease, cancer, immune system disorders, ophthalmic disease, and psychiatric and neurological disorders. Lexicon is working both independently and through strategic collaborations and alliances to accelerate the development and commercialization of its discoveries. Additional information about Lexicon is available through its corporate website, http://www.lexicon-genetics.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements about Lexicon`s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management`s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon`s ability to successfully conduct preclinical development of its drug candidates and advance such candidates into clinical development, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as those relating to manufacturing, the regulatory process, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon`s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Business - Risk Factors" in Lexicon`s annual report on Form 10-K for the year ended December 31, 2003, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.